Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

Former Iowa Hawkeyes basketball player Ava Jones announced her cancer diagnosis via Instagram on Saturday. In the Instagram ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Our body fat may turn out to be a secret weapon in our everlasting fight against cancer. A new study released this week ...

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new ...

Tea planter Vishal Mahindra was twice diagnosed with non-Hodgkin's lymphoma, a type of blood cancer that develops in the ...